Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.

ABSTRACT:

Background

Primary mediastinal B-cell lymphoma is a distinct subtype of diffuse large-B-cell lymphoma that is closely related to nodular sclerosing Hodgkin's lymphoma. Patients are usually young and present with large mediastinal masses. There is no standard treatment, but the inadequacy of immunochemotherapy alone has resulted in routine consolidation with mediastinal radiotherapy, which has potentially serious late effects. We aimed to develop a strategy that improves the rate of cure and obviates the need for radiotherapy.

Methods

We conducted a single-group, phase 2, prospective study of infusional dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (DA-EPOCH-R) and filgrastim without radiotherapy in 51 patients with unt

SUBMITTER: Dunleavy K 

PROVIDER: S-EPMC4568999 | biostudies-literature | 2013 Apr

REPOSITORIES: biostudies-literature